Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 194 publications
Setmelanotide for the Treatment of Acquired Hypothalamic Obesity.
Journal: The New England journal of medicine
Published: July 08, 2026
Evidence-informed guidance for the clinical use of oral semaglutide in obesity management.
Journal: Postgraduate medicine
Published: June 13, 2026
It's more than mechanics: the case for metabolic endpoints in airways disease.
Journal: The European respiratory journal
Published: May 17, 2026
Cortisol's role in difficult-to-control type 2 diabetes: Insights from the CATALYST study-a plain language review.
Journal: Current medical research and opinion
Published: May 13, 2026
Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study.
Journal: The lancet. Diabetes & endocrinology
Published: May 07, 2026
Beyond GLP1: modulating multiple nutrient-stimulated hormone pathways to reduce cardiovascular risk.
Beyond GLP1: modulating multiple nutrient-stimulated hormone pathways to reduce cardiovascular risk.
Journal: Nature reviews. Cardiology
Published: April 20, 2026
Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with type 2 diabetes (SOLSTICE): a multicentre, phase 2b, randomised, placebo-controlled trial.
Journal: Lancet (London, England)
Published: March 15, 2026
Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with obesity or overweight (VISTA): a multicentre, phase 2, randomised, placebo-controlled clinical trial.
Journal: Lancet (London, England)
Published: March 09, 2026
What REDEFINE 5 signals for obesity trials in Asia and beyond.
Journal: The lancet. Diabetes & endocrinology
Published: January 27, 2026
Last Updated: 09/26/2026